Cytogen 2026 Q1 consolidated revenue 6.4B won, operating loss 1.47B won, narrowing deficit

Consolidated revenue in Q1 2026: 6.4B won (+14% YoY).
Operating loss: 1.47B won (vs 3.76B won loss in Q1 2025), significantly narrowed.
Net loss: 1.27B won (vs 2.43B won loss in Q1 2025), improved.
Debt ratio improved to 67.2% (from 72.9% at end-2025).
Liquid Biopsy segment revenue: 3.1B won (48.6%); Genome analysis services: 2.94B won (46.1%).
Subsidiary Genome Care (genome analysis) posted net profit of 0.77B won in Q1.
Early redemption of 6th CB (3.3B won) and additional acquisition (6.5B won) reduced debt.
Pending lawsuit of USD 1.3M against ExperTox, but covered by insurance.